Nanobiotix (Euronext: NANO, NASDAQ: NBTX) announced results from Part 1 of the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE